CHRNA7 and Alzheimer disease: Disentangling the cell-type-specific contributions of α7-nAChRs could therefore open new routes for targeting prodromal synaptic failure in AD and refining therapeutic strategies aimed at preserving circuit function in the early stages of the disease.